Author

Meng A Xiao

Observed names: Meng A. Xiao, Meng Xiao

Institutions: Jewish General Hospital, Lady Davis Institute for Medical Research, Mark Wainberg Centre for Viral Diseases, McGill University

Observed institutions: Shanghai Jiao Tong University, Jewish General Hospital, Shanghai Ninth People's Hospital, Lady Davis Institute for Medical Research, Mark Wainberg Centre for Viral Diseases, McGill University

OpenAlex ID: A5010251930

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

2020 · Hanh Thi Pham, Meng A Xiao, et al. · Drugs in Context · 30

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

2023 · Meng A. Xiao, Jenna Cleyle, et al. · Antimicrobial Agents and Chemotherapy · 22

A 20(S)-protopanoxadiol derivative overcomes multi-drug resistance by antagonizing ATP-binding cassette subfamily B member 1 transporter function

2016 · Gang Chen, Junhua Liu, et al. · Oncotarget · 13

Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir

2020 · Hanh T Pham, Brunna M Alves, et al. · Journal of Antimicrobial Chemotherapy · 12

Works count: 4

Citation count: 77

H-index: 4

I10-index: 4